Global Infectious Disease Therapeutics Market 2019-2023 | Development of Novel Drugs to Boost Demand | Technavio
LONDON--(BUSINESS WIRE)--Dec 17, 2018--The global infectious disease therapeutics market is expected to post a CAGR of over 4% during the period 2019-2023, according to the latest market research report by .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181217005414/en/
Technavio has published a new market research report on the global infectious disease therapeutics market from 2019-2023. (Graphic: Business Wire)
A key factor driving the growth of the global infectious disease therapeutics market is the growing awareness of infectious diseases. Awareness campaigns for spotting the signs and symptoms of infectious diseases and methods of prevention play an important role in preventing the spread of such infections. For instance, Pfizer collaborated with the UAE government to increase the awareness of infectious diseases. Such initiatives to increase the awareness of infectious diseases will drive the market during the forecast period.
This market research report on the also provides an analysis of the most important trends expected to impact the market outlook during the forecast period. Technavio classifies an emerging trend as a major factor that has the potential to significantly impact the market and contribute to its growth or decline.
In this report, Technavio highlights the development of novel drugs as one of the key emerging trends in the global infectious disease therapeutics market:
Global infectious disease therapeutics market: Development of novel drugs
Over the years, there has been an increase in the R&D of novel drugs for the treatment of infectious diseases. For instance, researchers at the Indian Institute of Science have discovered a new drug combination that promises better outcomes in treating tuberculosis. Another discovery by the researchers at the University of Otago, New Zealand included the discovery of novel properties of a new antituberculosis drug called bedaquiline. Therefore, the emergence of novel drugs will boost the growth of the global infectious disease therapeutics market.
“Apart from the growing awareness of infectious diseases, factors such as the increasing prevalence of infectious diseases, and the strong drug pipeline will positively impact the growth of the global infectious disease therapeutics market during the forecast period,” says a senior analyst at Technavio for research on pharmaceuticals, biotechnology & life sciences.
Global infectious disease therapeutics market: Segmentation analysis
This market research report segments the global infectious disease therapeutics market by type (antiviral, antibacterial, and antifungal) and geographical regions (APAC, EMEA, and the Americas).
The Americas region led the market in 2018 with a market share of over 48%, followed by EMEA and APAC respectively. The Americas will see an increase in its market share and continue to dominate the market during the forecast period.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Market LandscapeMarket ecosystem Market characteristics Market segmentation analysis
Market SizingMarket definition Market size and forecast
Five Forces Analysis
Geographical SegmentationRegional comparison Key leading countries
Vendor LandscapeVendors covered Vendor classification Market positioning of vendors Competitive scenario
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20181217005414/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 12/17/2018 10:20 AM/DISC: 12/17/2018 10:20 AM